Author's response to reviews

Title: Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer

Authors:

Yoshinori Munemoto (Y-MUNEMOTO@fukui.saiseikai.or.jp)
Mitsuro Kanda (m-kanda@med.nagoya-u.ac.jp)
Keiichiro Ishibashi (k_ishi@saitama-med.ac.jp)
Taishi Hata (thata@gesurg.med.osaka-u.ac.jp)
Michiya Kobayashi (kobayasm@kochi-u.ac.jp)
Junichi Hasegawa (j-hasegawa@orh.go.jp)
Mutsumi Fukunaga (fukunaga1404@hp.pref.hyogo.jp)
Akinori Takagane (takagane@gobyou.com)
Toshio Otsuji (hxgcd792@yahoo.co.jp)
Yasuhiro Miyake (hotymiyake@hotmail.com)
Michitaka Nagase (mnagase@nagoya-1st.jrc.or.jp)
Junichi Sakamoto (sakamjun@med.nagoya-u.ac.jp)
Masaki Matsuoka (masa2722@mac.com)
Koji Oba (oba@epistat.m.u-tokyo.ac.jp)
Hideyuki Mishima (hmishima@aichi-med-u.ac.jp)

Version: 5
Date: 22 August 2015

Author's response to reviews:

August 22, 2015

Dafne Solera, PhD
Executive Editor,
BMC Cancer

Dear Dr. Solera,

We greatly appreciate your favorable comments and kind invitation to resubmit our manuscript (ID: 1037706307157790) titled “Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating Japanese patients at least 75 years of age with metastatic colorectal cancer.”

We revised the manuscript according to the Editor’s Additional Requests.

We hope that the revised manuscript is now acceptable for publication in BMC Cancer.

Best regards,

Mitsuro Kanda, MD, PhD
Department of Gastroenterological Surgery (Surgery II)
Nagoya University Graduate School of Medicine
65 Tsurumai-cho, Showa-ku, Nagoya 466-8550, Japan
Tel: +81-52-744-2249
Fax: +81-52-744-2252
E-mail: m-kanda@med.nagoya-u.ac.jp

#Editor's Additional Request#

1. Please include in the Methods section the full names of all the Ethics committees that approved the study at each participating center.
   Response: The full names of the Institutional Review Boards of all 18 participating centers were provided in the Methods section.

2. Please include an abbreviations section.
   Response: The abbreviations section was newly included in the text.